NCT01590771View on ClinicalTrials.gov

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

PHASE3CompletedINTERVENTIONAL
Enrollment

498

Participants

Timeline

Start Date

July 9, 2012

Primary Completion Date

June 10, 2014

Study Completion Date

June 24, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin

Sitagliptin 100 mg oral tablet once daily for 24 weeks

DRUG

Placebo

Matching placebo to sitagliptin oral tablet once daily for 24 weeks

DRUG

Gliclazide

Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.

DRUG

Glimepiride

Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.

DRUG

Metformin

Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01590771 - A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) | Biotech Hunter | Biotech Hunter